New combo therapy aims to deepen remission in CLL
NCT ID NCT05971251
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 24 times
Summary
This early-phase study tests adding a targeted drug, loncastuximab tesirine, to the standard treatment acalabrutinib for people with chronic lymphocytic leukemia (CLL). The main goal is to find the safest dose of the combination. Researchers will also check if the combo can make cancer undetectable in the blood at 6 and 12 months. About 24 adults with CLL will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.